MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

SAGE Therapeutics Company Profile (NASDAQ:SAGE)

Consensus Ratings for SAGE Therapeutics (NASDAQ:SAGE) (?)
Ratings Breakdown: 7 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $87.57 (29.24% upside)

Analysts' Ratings History for SAGE Therapeutics (NASDAQ:SAGE)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2015Canaccord GenuityBoost Price TargetBuy$85.00 -> $110.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015Cowen and CompanySet Price TargetBuy$95.00 -> $108.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015Leerink SwannSet Price TargetBuy$107.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2015Leerink SwannBoost Price TargetOutperform$70.00 -> $93.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/28/2015Cowen and CompanyInitiated CoverageOutperform$95.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/21/2015Canaccord GenuityBoost Price TargetBuy$58.00 -> $85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2015Goldman SachsInitiated CoverageBuy$80.00 -> $80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2015JPMorgan Chase & Co.Reiterated RatingBuy$58.00 -> $66.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2015Canaccord GenuityReiterated RatingBuy$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2015Leerink SwannSet Price TargetBuy$54.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2015JPMorgan Chase & Co.Boost Price TargetOverweight$51.00 -> $58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2015Canaccord GenuitySet Price TargetBuy$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2015JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2015William BlairInitiated CoverageOutperform$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2015Canaccord GenuitySet Price TargetBuy$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2015Canaccord GenuityReiterated RatingBuy$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2015SunTrustInitiated CoverageBuy$67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2015Canaccord GenuityReiterated RatingBuy$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/9/2015JPMorgan Chase & Co.Reiterated RatingOverweight$51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/9/2014Leerink SwannBoost Price TargetOutperform$46.00 -> $54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2014Goldman SachsUpgradeNeutral -> Buy$29.56 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2014Canaccord GenuityInitiated CoverageBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2014JPMorgan Chase & Co.Initiated CoverageOverweight$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2014Goldman SachsInitiated CoverageNeutral$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2014Leerink SwannInitiated CoverageOutperform$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/3/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha